Exosens · EURONEXT:EXENS
Exosens — H1 2025 Earnings Presentation
43 slides from Exosens's earnings presentation, Jul 30, 2025
Slide 1: First-Half 2025 Results
FIRST-HALF 2025 RESULTS 30 July 2025
Slide 2: Agenda
Agenda 1. Introduction 2. Market overview 3. Financial results 4. Outlook 5. Q&A 2
Slide 3: Exosens achieved a strong H1 2025 performance
Exosens achieved a strong H1 2025 performance €224.5m +20.1% Continued strong momentum Revenue Total revenue Growth YoY +13.2% LFL1 in Defense & Surveillance €69.5m 30.9% Evaluating additional staggered capacity Profitability Adj. EBITDA Adj. EBITDA margin increases to capture rising demand +23.8% Y
Slide 4: Introduction to Exosens
Ol Introduction to EXOSENS
Slide 5: We are a global leader in amplification and detection & imaging technologies
We are a global leader in amplification and detection & Imaging technologies Leader Global Technology and R&D Strong in niche growing commercial financials markets1 reach powerhouse Top 1-2 player 300+ customers ~7.7% of revenue €394m in most of addressed markets with industry invested in gross R&D2
Slide 6: We focus on markets with long-term structural growth drivers
We focus on markets with long-term structural growth drivers Return of high-density conflict threats More effective treatments Protect the defense forces Diagnose pathologies earlier Key tactical advantages at night Fast and more reliable devices Short acquisition cycles, Environmental protection fa
Slide 7: We are a technology platform in amplification and detection & imaging technologies
We are a technology platform in amplification and detection & Imaging technologies Radio Ion / Electron Neutron / Gamma X-Rays UV VIS SWIR MWIR LWIR Microwaves waves Wavelength (nm) 100 380 750 1,000 2,500 8,000 14,000 Time of flight Boron line Micro pore Intensified 4G/4G+ Imaging Cooled Infra-red
Slide 8: Transforming cutting edge technology to fuel our growth
Transforming cutting edge technology to fuel our growth Innovation is in our DNA We leverage a global ecosystem of cutting-edge partners Optics Raw materials ~7.7% of revenue Infra-Red Hyper- invested in gross R&D1 spectral X-ray Single Photon 230+ ~85 PhDs Artificial proven technology evolving in R
Slide 9: Accelerating growth with selective acquisitions of technologies
Accelerating growth with selective acquisitions of technologies Value additive M&A Technology Go-To-Market Synergies • Additional light & particle • Accelerate go-to-market in • Global commercial reach spectrum technologies in high-value high-value added added niches niches with cross-selling potent
Slide 10: A well embedded sustainability strategy within products and operations
A well embedded sustainability strategy within products and operations enabling societal and environmental protection Ecovadis Silver UN Global Compact Signatory Medal 2024 UN Sustainable Development Goals Alignment Selected targets Partnership with • 80% of strategic suppliers1 committed to a CSR a
Slide 11: Market overview
EXOSENS REVEAL THE INVISIBLE O2 Market overview
Slide 12: Despite rising defense spending, EU NATO countries remain below 3.5% target
DEFENSE & NUCLEAR INDUSTRIAL LIFESCIENCE & SURVEILLANCE INSTRUMENTATION CONTROL ENVIRONMENT Despite rising defense spending, EU NATO countries remain well below the new 3.5% of GDP target New objectives agreed to target 3.5% in NATO summit end of June 2025: Exosens is well positioned to benefit from
Slide 13: Massive Demand Ahead: 1 Million NV devices seen as of today
DEFENSE & NUCLEAR INDUSTRIAL LIFESCIENCE & SURVEILLANCE INSTRUMENTATION CONTROL ENVIRONMENT Massive Demand Ahead: 1 Million NV devices seen as of today Demand constantly increasing as NATO Countries still Lag Behind the 1:1 Equipment-to-Soldier Target North America Europe Middle East & Asia NV penet
Slide 14: Well positioned to capture increasing demand in Europe, APAC while gaining traction in US
DEFENSE & NUCLEAR INDUSTRIAL LIFESCIENCE & SURVEILLANCE INSTRUMENTATION CONTROL ENVIRONMENT Exosens is well positioned to capture increasing demand in Europe, APAC while also gaining traction in the US market UNITED STATES EUROPE Middle East & Asia Key opportunities : Key opportunities : Key opportu
Slide 15: Staggered capacity expansion underway to capture upcoming demand surge
DEFENSE & NUCLEAR INDUSTRIAL LIFESCIENCE & SURVEILLANCE INSTRUMENTATION CONTROL ENVIRONMENT Staggered capacity expansion underway to capture most of the upcoming demand surge Light amplification capacity plan Staggered approach to capacity increase Maximum usable production in place since 2020 capac
Slide 16: Modern warfare sets a new paradigm: drones and counter-drones
DEFENSE & NUCLEAR INDUSTRIAL LIFESCIENCE & SURVEILLANCE INSTRUMENTATION CONTROL ENVIRONMENT Modern warfare sets a new paradigm and is key to maintaining military superiority Drones Counter-drones systems Ukraine war confirm drones as a game changer Need for long range surveillance to detect massive
Slide 17: Platform markets booming amid fleet modernization
DEFENSE & NUCLEAR INDUSTRIAL LIFESCIENCE & SURVEILLANCE INSTRUMENTATION CONTROL ENVIRONMENT Platform markets booming amid fleet modernization and expansion by major European NATO members Platform protection: Vehicles Missiles Warning Systems Shift toward high-intensity combat Increasing missiles thr
Slide 18: Nuclear Power: ~2x expected increase in nuclear capacity by 2050
DEFENSE & NUCLEAR INDUSTRIAL LIFESCIENCE & SURVEILLANCE INSTRUMENTATION CONTROL ENVIRONMENT Nuclear Power: ~2x expected increase in nuclear capacity by 2050 Nuclear reactor plants SMR Research reactors • Long-lasting • Strong involvements in • Exosens contributes relationship in France key major SMR
Slide 19: Industrial Control market expectations remain robust
DEFENSE & NUCLEAR INDUSTRIAL LIFESCIENCE & SURVEILLANCE INSTRUMENTATION CONTROL ENVIRONMENT Industrial Control market expectations remain robust: Multiple drivers support mid-term market growth Slight market recovery driven by : 01 02 03 MARKETS Impact of artificial intelligence + Restart of new + R
Slide 20: Market softness with sustainable drivers in the mid-term
DEFENSE & NUCLEAR INDUSTRIAL LIFESCIENCE & SURVEILLANCE INSTRUMENTATION CONTROL ENVIRONMENT Market softness with sustainable drivers in the mid-term 01 02 03 MARKETS Higher performance requirements US : Cost savings on Pharmaceutical China : Geo-political situation for Mass Spectrometry + as part of
Slide 21: Financial results
EXOSENS REVEAL THE INVISIBLE O3 Financial results St
Slide 22: High revenue growth and margin expansion
High revenue growth and margin expansion Pursuing our strong profitable growth trajectory Revenue (in €M) Adjusted gross margin (in €M) Change % sales Change % sales +13.2% LFL1 48.8% 49.6% +20.1% +22.3% 11.9 1.3 224.5 4.5 (0.2) 111.5 24.4 16.0 186.9 91.1 H1 24 Amplification D&I Eliminations H1 25 H
Slide 23: Double-digits growth across both segments
Double-digits growth across both segments Fueled by strong Defense momentum Amplification (in €M) Detection and Imaging (in €M) Revenue Adj. gross margin Revenue Adj. gross margin Change % sales Change % sales -2.5% LFL1 Change % sales Change % sales +17.6% 47.1% +24.5% 49.8% +23.6% 51.1% +17.6% 48.
Slide 24: Further improvement in our profitability
Further improvement in our profitability Delivering best-in-class margins Adjusted EBITDA Adjusted EBIT Margin drivers Change Change In €M +23.8% In €M +27.1% 69.5 58.6 56.1 46.1 Volume / scale H1 24 H1 25 H1 24 H1 25 % sales +92bps % sales +142bps Favorable product mix 30.9% 26.1% 30.0% 24.7% H1 24
Slide 25: Strong growth in net profit to €28m
Strong growth in net profit to €28m Reflecting our ability to grow profitably Comments In €m H1 2024 H1 2025 Change Current operating profit 34.5 46.8 +12.3 1. One-off consulting fees related to IPO Other income / (expenses) 1 (3.9) 0.0 +3.8 2. H1 24 financial result1 reflected the capital structure
Slide 26: Continued high investment in R&D
Continued high investment in R&D Supporting our innovation capabilities R&D (in €M) Comments % sales Change % sales • Continued R&D investment as a primary 7.9% Gross R&D 7.6% engine for growth and a cornerstone of the Group’s technological leadership 6.3% Net R&D1 6.0% • Gross R&D up +€2.3m in H1 2
Slide 27: Ongoing investment in capacity and productivity
Ongoing investment in capacity and productivity Securing our future growth Capital expenditure (in €M) Comments % sales Change % sales • Total capex up +€2.0m in H1 25 (+15.5%) 7.0% Total 6.7% • Growth capex up +€2.5m (+34.3%), mainly allocated to machinery and 3.9% Growth 4.3% tools, driving steady
Slide 28: Robust free cash flow generation
Robust free cash flow generation Cash conversion of 76% In €m H1 2024 H1 2025 Change Comments Adjusted EBITDA 56.1 69.5 +13.4 Robust FCF generation of €23.6m in H1 25, stable vs. H1 24, amid higher investment to Capitalized R&D (4.6) (6.1) +0.3 support future growth Adjusted EBITDA post capitalized
Slide 29: Sound balance sheet at end June 2025
Sound balance sheet at end June 2025 Supporting our growth strategy Debt structure (in €M) Leverage ratio1 (x) Comments 1.3x Strong liquidity with cash IFRS 16 lease 17.4 position of €88.8m and & Other €100m undrawn RCF Term loan 1.2x maturity 2029 Term loan 250.0 Net debt of €178.6m Leverage ratio
Slide 30: Outlook
© EXOSENS REVEAL THE INVISIBLE O4 Outlook
Slide 31: Outlook for 2025 and the 2024-2026 period
Outlook for 2025 and the 2024-2026 period Fully on track to deliver on our guidance 01 02 03 Revenue growth1 Adj. EBITDA CAGR Continuing selective M&A in the high teens in the high teens strategy while maintaining in 2025 vs. 2024 over 2024-2026 a leverage ratio3 of ~2x Adj. EBITDA growth Additional
Slide 32: Questions / Answers
© EXOSENS REVEAL THE INVISIBLE O5 Questions / Answers
Slide 33: Appendices
EXOSENS REVEAL THE INVISIBLE Appendices
Slide 34: Revenue and adj. gross margin by segment
Revenue and adj. gross margin by segment In €m 2024 2025 Change (%) Like-for-like (%) Q1 Q2 H1 Q1 Q2 H1 Q1 Q2 H1 Q1 Q2 H1 Revenue 86.7 100.2 186.9 104.9 119.6 224.5 +21.1% +19.3% +20.1% +18.0% +9.0% +13.2% • Amplification 63.3 75.2 138.5 81.8 81.1 162.9 +29.1% +8.0% +17.6% +29.3% +7.9% +17.7% • Dete
Slide 35: Key performance indicators
Key performance indicators In €m H1 2024 H1 2025 Change In €m % sales In €m % sales In % Revenue 186.9 100.0% 224.5 100.0% +20.1% Adjusted gross margin 91.1 48.8% 111.5 49.6% +22.3% Indirect costs (35.0) (18.7%) (42.0) (18.7)% +20.0% Adjusted EBITDA 56.1 30.0% 69.5 30.9% +23.8% Depreciation, amortiz
Slide 36: Reconciliation of adj. EBITDA and adj. EBIT
Reconciliation of adj. EBITDA and adj. EBIT In €m H1 2024 H1 2025 Comments Operating profit 30.7 46.7 Depreciation, amortisation and impairment - net 15.9 18.2 1. One-off consulting fees related to the 1 IPO Other income and expenses 3.9 0.1 EBITDA 50.4 65.0 2. Costs mainly related to consultancy an
Slide 37: Income statement
Income statement In €m H1 2024 H1 2025 Revenue 186.9 224.5 Cost of sales (45.6) (51.6) Other purchases and external expenses (33.9) (35.8) Taxes and duties other than income tax (1.2) (1.1) Employee benefits expenses (55.5) (69.4) Other operating income / (expenses) (0.6) 0.7 Depreciation, amortizat
Slide 38: Cash flow statement
Cash flow statement In €m H1 2024 H1 2025 Net profit / (loss) 2.9 27.9 Net financial results 25.7 8.3 Income tax 2.1 10.5 Charges net of reversals to depreciation and amortization 15.5 20.3 Other income / (expenses) 2.9 2.0 Income tax received / (paid) (1.6) (3.5) Change in net working capital (7.7)
Slide 39: Balance sheet – Assets
Balance sheet – Assets In €m 31-Dec-2024 30-Jun-2025 Goodwill 189.5 209.2 Intangible assets 204.9 221.2 Tangible assets 93.6 100.9 Right-of-use of leases 10.6 18.3 Investment in associates 3.4 3.4 Financial assets and other long-term investments 0.9 0.6 Deferred tax assets - - Non-current assets 502
Slide 40: Balance sheet – Equity & liabilities
Balance sheet – Equity & liabilities In €m 31-Dec-2024 30-Jun-2025 Share capital 21.6 21.6 Additional paid-in capital 342.5 342.5 Reserves 48.5 65.4 Total equity 412.6 429.5 Long-term financial debt 247.8 247.5 Long-term lease liabilities 8.2 15.9 Pension liabilities 7.5 7.4 Provisions and other lon
Slide 41: Financial glossary
Financial glossary Like-for-like growth Like-for-like growth is the revenue growth achieved by the Group excluding currency impact and scope effect, which corresponds to the revenue recorded during the period “n” by all the companies included in the Group’s scope of consolidation at the end of the p
Slide 42: Financial calendar
Financial calendar 27 October 2025 Third Quarter 2025 Revenue & Adj. Gross Margin 23 February 2026 Full-Year 2025 Results 27 April 2026 First Quarter 2026 Revenue & Adj. Gross Margin 28 July 2026 First-Half 2026 Results 42
Slide 43: Exosens
EXOSENS REVEAL THE INVISIBLE